Assembly Biosciences, Inc. (ASMB) Total liabilities 2016–2025
Assembly Biosciences, Inc. (ASMB) total liabilities at each fiscal year-end, per SEC filings.
$50.8MFY2025 · since FY2016: $18.2M → $50.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $50.8M | -40.8% |
| FY2024 | $85.8M | -10.4% |
| FY2023 | $95.7M | +400.4% |
| FY2022 | $19.1M | -13.6% |
| FY2021 | $22.1M | -48.1% |
| FY2020 | $42.7M | -36.0% |
| FY2019 | $66.7M | +16.2% |
| FY2018 | $57.4M | +2.2% |
| FY2017 | $56.2M | +208.0% |
| FY2016 | $18.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ASMB financial trends
ASMB RevenueASMB Net incomeASMB Net marginASMB Gross profitASMB Gross marginASMB Operating incomeASMB Operating marginASMB Operating cash flowASMB Free cash flowASMB Capital expendituresASMB Return on equityASMB Stock buybacksASMB Dividends paidASMB Total assetsASMB Shareholders’ equityASMB overview →